Histone deacetylase inhibitors
US-9908899-B2 · Mar 6, 2018 · US
Histone deacetylase inhibitors
US10280182B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10280182-B2 |
| Application number | US-201816046382-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2018 |
| Priority date | Feb 28, 2011 |
| Publication date | May 7, 2019 |
| Grant date | May 7, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
First claim
Opening claim text (preview).
We claim: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound or salt of claim 1 , having a structure: 3. The compound or salt of claim 1 , having a structure: 4. The compound or salt of claim 1 , having a structure: 5. The compound or salt of claim 1 , having a structure: 6. The compound or salt of claim 1 , having a structure: 7. The compound or salt of claim 1 , having a structure: 8. The compound or salt of claim 1 , having a structure: 9. The compound or salt of claim 1 , having a structure: 10. The compound or salt of claim 1 , having a structure:
Assignees
Inventors
Classifications
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title
Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical · CPC title
with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Ortho-condensed systems · CPC title
- C07D513/04Primary
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10280182B2 cover?
- This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
- Who is the assignee on this patent?
- Biomarin Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).